

Supplementary Online Content

Vettenranta A, Murtola TJ, Raitanen J, et al. Outcomes of screening for prostate cancer among men who use statins. Published online November 24, 2021. *JAMA Oncol*. doi:10.1001/jamaoncol.2021.5672

eFigure. Distribution of PSA Values by Statin Use Before Prostate Cancer Diagnosis

eTable 1. Descriptive Characteristics Information About Gleason Grades and Metastatic Status by Statin Use


eTable 2. Effect of PSA-Based Screening on Incidence of Prostate Cancer Overall and Clinically Nonsignificant Disease as Defined by Gleason Score and TNM Stage

eTable 3. Effect of Screening on Prostate Cancer–Specific Mortality Among Users and Nonusers of Statins

eTable 4. Prostate Cancer Incidence Among Statin Users by Statin Dose

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Distribution of PSA Values by Statin Use Before Prostate Cancer Diagnosis



eTable 1. Descriptive Characteristics Information About Gleason Grades and Metastatic Status by Statin Use

Study population of 78,606 men from the Finnish Randomized Study of Prostate Cancer Screening.

	FinRSPC study arm			
	Screening arm		Control arm	
	Statin users	Statin non-users	Statin users	Statin non-users
Number of participants	12,059	18,277	19,567	28,703
Tumor grade at diagnosis				
Gleason 6 or less; n (% of diagnoses)	549 (51%)	1,575 (61%)	690 (40%)	1,464 (46%)
Gleason 7; n (%)	319 (30%)	639 (25%)	630 (37%)	1,020 (32%)
Gleason 8-10; n (%)	190 (18%)	334 (13%)	363 (21%)	585 (18%)
Unknown	14 (1%)	52 (2%)	35 (2%)	103 (3%)
Tumor T-stage at diagnoses				
T1/T2	895 (83%)	2,196 (84%)	1,335 (78%)	2,369 (75%)
T3	144 (13%)	320 (12%)	305 (18%)	618 (19%)
T4	29 (3%)	71 (3%)	66 (4%)	165 (5%)
Unknown	4 (0.4%)	13 (0.5%)	12 (1%)	20 (1%)
Tumor M-stage at diagnosis				
Localized (M0/x); n (%)	986 (92%)	2,398 (92%)	1,552 (90%)	2,784 (88%)
Metastatic (M1); n (%)	86 (8%)	202 (8%)	164 (10%)	387 (12%)

FinRSPC = Finnish Randomized Study of Screening for Prostate Cancer

eTable 2. Effect of PSA-Based Screening on Incidence of Prostate Cancer Overall and Clinically Nonsignificant Disease as Defined by Gleason Score and TNM Stage

Study population of 78,606 men from the Finnish Randomized Study of Screening for Prostate Cancer

Status of statin use none/any	PCa incidence, overall	Gleason 6 or less	Localized prostate cancer	Gleason 7	Gleason 8-10	Advanced PCa ^a
	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)
n of users/non-users	31,625/46,978	29,856/43,966	31,337/46,338	29,620/42,610	29,178/41,831	28,828/41,436
Never-use of statins	1.31 (1.24-1.38)	1.70 (1.58-1.82)	1.37 (1.30-1.45)	1.00 (0.91-1.11)	0.91 (0.80-1.04)	0.83 (0.70-0.99)
Any use of statins	1.02 (0.95-1.10)	1.29 (1.15-1.44)	1.04 (0.96-1.13)	0.83 (0.72-0.95)	0.85 (0.72-1.02)	0.85 (0.66-1.11)
P for interaction	<0.001	<0.001	<0.001	0.02	0.56	0.90
Intensity of statin use						
Under 0.65 defined dose/day	0.96 (0.85-1.08)	1.31 (1.11-1.56)	0.99 (0.87-1.12)	0.68 (0.54-0.85)	0.74 (0.55-0.99)	0.67 (0.44-1.03)
0.65 – 1.08 defined dose/day	1.09 (0.96-1.25)	1.36 (1.12-1.65)	1.13 (0.98-1.29)	0.89 (0.71-1.13)	0.89 (0.66-1.20)	0.81 (0.51-1.28)
Over 1.08 defined dose/day	1.02 (0.88-1.18)	1.12 (0.88-1.41)	1.00 (0.86-1.17)	0.96 (0.75-1.22)	0.96 (0.69-1.33)	1.24 (0.76-2.02)

Abbreviations: FinRSPC= Finnish Randomized Study of Screening for Prostate Cancer, RR = rate ratio, CI = confidence interval, PSA = Prostate-specific antigen ^a Prostate cancer cases with T-stage T3b or higher, all N1 and M1

eTable 3. Effect of Screening on Prostate Cancer–Specific Mortality Among Users and Nonusers of Statins

Study population of 78,606 men from the Finnish Randomized Study of Screening for Prostate Cancer

Status of statin use none/any	FinRSPC control arm		FinRSPC screening arm	
	N of men/prostate cancer deaths		N of men/prostate cancer deaths	
Never-use of statins	28,701/372		18,277/212	
Any use of statins	19,566/125		12,059/75	
P for interaction			0.50	
Intensity of statin use				
Under 0.65 defined dose/day	6,486/55		4,059/30	
0.65 – 1.08 defined dose/day	6,499/43		4,042/25	
Over 1.08 defined dose/day	6,581/27		3,958/20	
			RR (95% CI)	
			0.87 (0.73-1.03)	
			0.97 (0.73-1.30)	
			0.85 (0.54-1.32)	
			0.95 (0.58-1.55)	
			1.24 (0.70-2.22)	

Abbreviations: FinRSPC= Finnish Randomized Study of Screening for Prostate Cancer, RR = rate ratio, CI = confidence interval

eTable 4. Prostate Cancer Incidence Among Statin Users by Statin Dose

Study population of 78,606 men from the Finnish Randomized Study of Screening for Prostate Cancer.

	Screening Arm		Control arm	
Intensity of statin use	Incidence per 1000 pys	95% CI	Incidence per 1000 pys	95% CI
Under 0.65 defined dose/day	7.49	6.79-8.24	7.74	7.18-8.34
0.65 – 1.08 defined dose/day	6.13	5.52-6.78	5.65	5.17-6.11
Over 1.08 defined dose/day	4.46	3.95-5.02	4.42	4.03-4.84

Abbreviations: pys = person years CI = confidence interval